MED logo

Medifast (MED) Company Overview

Profile

Full Name:

Medifast, Inc.

Country:

United States

IPO:

December 30, 1993

Indexes:

Not included

Description:

Medifast, Inc. is an American company that specializes in the development, production, and sales of special nutrition and weight control programs, as well as products for a healthy lifestyle. The company is based in Baltimore, Maryland and was founded in 1980. Medifast, Inc.'s products and programs are developed in collaboration with scientists and doctors specifically for clients to help them achieve optimal weight and get into a healthy shape. The company's products focus on developing the right dietary plan for each client, motivation and workout programs, and instilling healthy habits.

Key Details

Price

$15.49

Annual Revenue

$1.07 B(-32.94% YoY)

Annual EPS

$9.10(-28.52% YoY)

Beta

0.47

Events Calendar

Earnings

Next earnings date:

Feb 20, 2025

Recent quarterly earnings:

Nov 4, 2024

Recent annual earnings:

Feb 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Sep 18, 2023
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 5, 24 DA Davidson
Neutral
Jul 22, 24 DA Davidson
Underperform
Jun 5, 24 DA Davidson
Underperform
Apr 30, 24 DA Davidson
Neutral
Feb 21, 24 DA Davidson
Neutral
Oct 13, 23 Stephens & Co.
Equal-Weight
Aug 8, 23 DA Davidson
Neutral
Jul 31, 23 DA Davidson
Neutral
May 2, 23 DA Davidson
Neutral
Feb 22, 23 DA Davidson
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Medifast Launches OPTAVIA ASCEND for Weight Loss Management
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED
zacks.comJanuary 8, 2025

MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.

How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
MED
zacks.comNovember 19, 2024

MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.

Are Investors Undervaluing MEDIFAST (MED) Right Now?
Are Investors Undervaluing MEDIFAST (MED) Right Now?
Are Investors Undervaluing MEDIFAST (MED) Right Now?
MED
zacks.comNovember 7, 2024

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
MED
zacks.comNovember 5, 2024

Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.

Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
MED
seekingalpha.comNovember 4, 2024

Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call.

Medifast Drives Growth With Weight Loss Transformation Strategies
Medifast Drives Growth With Weight Loss Transformation Strategies
Medifast Drives Growth With Weight Loss Transformation Strategies
MED
zacks.comOctober 7, 2024

MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.

The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Inquiry Into Medifast, Inc.
MED
accesswire.comSeptember 27, 2024

LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc Is Being Investigated For Violating Securities Laws And Investors Are Urged To Contact The Schall Law Firm
Medifast Inc Is Being Investigated For Violating Securities Laws And Investors Are Urged To Contact The Schall Law Firm
Medifast Inc Is Being Investigated For Violating Securities Laws And Investors Are Urged To Contact The Schall Law Firm
MED
accesswire.comSeptember 26, 2024

LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Medifast, Inc. For Securities Fraud
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Medifast, Inc. For Securities Fraud
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Medifast, Inc. For Securities Fraud
MED
accesswire.comSeptember 21, 2024

LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medifast Inc May Have Violated Securities Laws And Investors Are Urged To Help The Schall Law Firm Investigate
Medifast Inc May Have Violated Securities Laws And Investors Are Urged To Help The Schall Law Firm Investigate
Medifast Inc May Have Violated Securities Laws And Investors Are Urged To Help The Schall Law Firm Investigate
MED
accesswire.comSeptember 20, 2024

LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

FAQ

  • What is the ticker symbol for Medifast?
  • Does Medifast pay dividends?
  • What sector is Medifast in?
  • What industry is Medifast in?
  • What country is Medifast based in?
  • When did Medifast go public?
  • Is Medifast in the S&P 500?
  • Is Medifast in the NASDAQ 100?
  • Is Medifast in the Dow Jones?
  • When was Medifast's last earnings report?
  • When does Medifast report earnings?
  • Should I buy Medifast stock now?

What is the ticker symbol for Medifast?

The ticker symbol for Medifast is NYSE:MED

Does Medifast pay dividends?

No, Medifast does not pay dividends

What sector is Medifast in?

Medifast is in the Consumer Cyclical sector

What industry is Medifast in?

Medifast is in the Personal Services industry

What country is Medifast based in?

Medifast is headquartered in United States

When did Medifast go public?

Medifast's initial public offering (IPO) was on December 30, 1993

Is Medifast in the S&P 500?

No, Medifast is not included in the S&P 500 index

Is Medifast in the NASDAQ 100?

No, Medifast is not included in the NASDAQ 100 index

Is Medifast in the Dow Jones?

No, Medifast is not included in the Dow Jones index

When was Medifast's last earnings report?

Medifast's most recent earnings report was on Nov 4, 2024

When does Medifast report earnings?

The next expected earnings date for Medifast is Feb 20, 2025

Should I buy Medifast stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions